Cash flow Iqvia Holdings Inc.

Equities

IQV

US46266C1053

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:02 2025-12-09 pm EST			5-day change	1st Jan Change
218.06 ^USD	-2.46%		-3.36%	+10.97%

Dec. 08	Halozyme Therapeutics, Inc. Announces Election of Jim Lang to Board of Directors, Effective December 4, 2025	CI
Dec. 02	Amneal Pharmaceuticals, Inc. Receives U.S. Fda Approval for Albuterol Sulfate Inhalation Aerosol	CI

48eaa677416aed05.r80N8LC4V50o15bMYN1_92-EPE4737_lwuaqI7AGmhA.7bVJxvbvGdMFtsC6BokduwC9fQN97PejgIzvUslcwEHknUuJxcIxyGCtrg

Published financial data: IQVIA HOLDINGS INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2020	2021	2022	2023	2024
Revenues	11.36B	13.87B	14.41B	14.98B	15.4B
Total Revenues	11.36B	13.87B	14.41B	14.98B	15.4B
Cost of Goods Sold, Total	7.5B	9.23B	9.38B	9.74B	10.03B
Gross Profit	3.86B	4.64B	5.03B	5.24B	5.38B
Selling General & Admin Expenses, Total	1.76B	1.93B	2.04B	2.04B	1.98B
Depreciation & Amortization - (IS)	1.29B	1.26B	1.13B	1.12B	1.11B
Other Operating Expenses	-	-	-	-	-
Other Operating Expenses, Total	3.05B	3.2B	3.17B	3.17B	3.1B
Operating Income	810M	1.45B	1.86B	2.07B	2.28B
Interest Expense, Total	-416M	-375M	-416M	-672M	-670M
Interest And Investment Income	6M	6M	13M	36M	47M
Net Interest Expenses	-410M	-369M	-403M	-636M	-623M
Income (Loss) On Equity Invest.	7M	6M	-12M	-	5M
Currency Exchange Gains (Loss)	-1M	-	-	-	-
Other Non Operating Income (Expenses)	-5M	38M	-54M	36M	-13M
EBT, Excl. Unusual Items	401M	1.12B	1.39B	1.47B	1.65B
Restructuring Charges	-52M	-20M	-28M	-84M	-67M
Merger & Related Restructuring Charges	-	-	-	-	-
Impairment of Goodwill	-	-	-	-	-
Gain (Loss) On Sale Of Investments	25M	16M	-27M	20M	22M
Asset Writedown	-	-	-	-	-
Other Unusual Items	6M	17M	15M	52M	71M
EBT, Incl. Unusual Items	380M	1.13B	1.35B	1.46B	1.67B
Income Tax Expense	72M	163M	260M	101M	301M
Earnings From Continuing Operations	308M	971M	1.09B	1.36B	1.37B
Net Income to Company	308M	971M	1.09B	1.36B	1.37B
Minority Interest	-29M	-5M	-	-	-
Net Income - (IS)	279M	966M	1.09B	1.36B	1.37B
Net Income to Common Incl Extra Items	279M	966M	1.09B	1.36B	1.37B
Net Income to Common Excl. Extra Items	279M	966M	1.09B	1.36B	1.37B
Per Share Items
Net EPS - Basic	1.46	5.05	5.82	7.39	7.57
Basic EPS - Continuing Operations	1.46	5.05	5.82	7.39	7.57
Basic Weighted Average Shares Outstanding	191M	191M	188M	184M	181M
Net EPS - Diluted	1.43	4.95	5.72	7.29	7.49
Diluted EPS - Continuing Operations	1.43	4.95	5.72	7.29	7.49
Diluted Weighted Average Shares Outstanding	195M	195M	191M	186M	183M
Normalized Basic EPS	1.16	3.63	4.63	5	5.68
Normalized Diluted EPS	1.14	3.57	4.56	4.93	5.62
Supplemental Items
EBITDA	1.83B	2.5B	2.57B	2.72B	2.92B
EBITA	1.7B	2.35B	2.41B	2.57B	2.77B
EBIT	810M	1.45B	1.86B	2.07B	2.28B
EBITDAR	2.04B	2.68B	2.74B	2.88B	3.08B
Total Revenues (As Reported)	-	-	-	-	-
Effective Tax Rate - (Ratio)	18.95	14.37	19.24	6.92	17.98
Current Domestic Taxes	-	16M	24M	21M	44M
Current Foreign Taxes	244M	293M	358M	349M	386M
Total Current Taxes	244M	309M	382M	370M	430M
Deferred Domestic Taxes	-161M	-106M	-94M	-236M	-116M
Deferred Foreign Taxes	-11M	-40M	-28M	-33M	-13M
Total Deferred Taxes	-172M	-146M	-122M	-269M	-129M
Normalized Net Income	222M	696M	869M	919M	1.03B
Non-Cash Pension Expense	-27M	-33M	-33M	-10M	-10M
Supplemental Operating Expense Items
Advertising Expense	-	-	-	-	-
Selling and Marketing Expenses	-	-	-	-	-
Research And Development Expense From Footnotes	-	-	-	-	-
Net Rental Expense, Total	209M	184M	171M	160M	158M
Imputed Operating Lease Interest Expense	54.96M	42.88M	44.09M	63.03M	59.57M
Imputed Operating Lease Depreciation	154M	141M	127M	96.97M	98.43M
Stock-Based Comp., SG&A Exp. (Total)	95M	170M	194M	217M	206M
Total Stock-Based Compensation	95M	170M	194M	217M	206M

Fiscal Period: December	2020	2021	2022	2023	2024
Assets
Cash And Equivalents	1.81B	1.37B	1.22B	1.38B	1.7B
Short Term Investments	88M	111M	93M	120M	141M
Trading Asset Securities, Total	-	-	-	-	-
Total Cash And Short Term Investments	1.9B	1.48B	1.31B	1.5B	1.84B
Accounts Receivable, Total	2.41B	2.55B	2.92B	3.38B	3.2B
Other Receivables	56M	58M	43M	32M	36M
Total Receivables	2.47B	2.61B	2.96B	3.41B	3.24B
Prepaid Expenses	159M	156M	151M	141M	154M
Deferred Tax Assets Current	-	-	-	-	-
Restricted Cash	-	-	-	-	-
Other Current Assets, Total	563M	521M	561M	546M	592M
Total Current Assets	5.09B	4.76B	4.98B	5.6B	5.83B
Gross Property Plant And Equipment	1.63B	1.67B	1.7B	1.62B	1.59B
Accumulated Depreciation	-673M	-765M	-840M	-803M	-819M
Net Property Plant And Equipment	953M	903M	863M	819M	773M
Long-term Investments	162M	168M	162M	239M	374M
Goodwill	12.65B	13.3B	13.92B	14.57B	14.71B
Other Intangibles, Total	5.2B	4.94B	4.82B	4.84B	4.5B
Deferred Tax Assets Long-Term	114M	124M	118M	166M	194M
Deferred Charges Long-Term	-	-	-	-	-
Other Long-Term Assets, Total	386M	487M	472M	455M	520M
Total Assets	24.56B	24.69B	25.34B	26.68B	26.9B
Liabilities
Accounts Payable, Total	581M	621M	645M	709M	736M
Accrued Expenses, Total	1.27B	1.42B	1.49B	1.48B	1.42B
Current Portion of Long-Term Debt	149M	91M	152M	769M	1.15B
Current Portion of Leases	156M	149M	116M	107M	105M
Current Income Taxes Payable	102M	137M	161M	116M	156M
Unearned Revenue Current, Total	2.1B	2.71B	2.86B	3.11B	3.24B
Other Current Liabilities	198M	119M	152M	199M	153M
Total Current Liabilities	4.56B	5.24B	5.58B	6.49B	6.96B
Long-Term Debt	12.44B	12.06B	12.6B	12.96B	12.84B
Long-Term Leases	493M	490M	488M	451M	391M
Pension & Other Post Retirement Benefits	257M	231M	179M	214M	221M
Deferred Tax Liability Non Current	338M	410M	464M	202M	196M
Other Non Current Liabilities	198M	217M	268M	256M	229M
Total Liabilities	18.28B	18.65B	19.57B	20.57B	20.83B
Common Stock, Total	3M	3M	3M	3M	3M
Additional Paid In Capital	11.09B	10.77B	10.9B	11.02B	11.14B
Retained Earnings	1.28B	2.24B	3.33B	4.69B	6.06B
Treasury Stock	-6.17B	-6.57B	-7.74B	-8.74B	-10.1B
Comprehensive Income and Other	-205M	-406M	-727M	-867M	-1.04B
Total Common Equity	6B	6.04B	5.76B	6.11B	6.07B
Minority Interest	279M	-	-	-	-
Total Equity	6.28B	6.04B	5.76B	6.11B	6.07B
Total Liabilities And Equity	24.56B	24.69B	25.34B	26.68B	26.9B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	191M	190M	186M	182M	176M
ECS Total Common Shares Outstanding	191M	191M	186M	182M	176M
Book Value / Share	31.39	31.7	31.04	33.67	34.45
Tangible Book Value	-11.86B	-12.2B	-12.98B	-13.29B	-13.14B
Tangible Book Value Per Share	-62.02	-64.02	-69.88	-73.25	-74.63
Total Debt	13.24B	12.79B	13.35B	14.28B	14.48B
Net Debt	11.34B	11.31B	12.04B	12.79B	12.64B
Debt Equivalent of Unfunded Proj. Benefit Obligation	244M	122M	87M	94M	74M
Debt Equivalent Oper. Leases	1.67B	1.47B	1.37B	1.28B	1.26B
Minority Interest, Total (Incl. Fin. Div)	279M	-	-	-	-
Equity Method Investments, Total	84M	88M	94M	134M	266M
Account Code - Inventory Valuation	3	3	-	-	3
Land - (BS)	351M	376M	363M	376M	367M
Machinery, Total	804M	886M	1.01B	950M	987M
Full Time Employees	70K	79K	86K	87K	88K
Accumulated Allowance for Doubtful Accounts (Supple)	34M	33M	36M	34M	42M
Order Backlog	22.6B	24.8B	27.2B	29.7B	31.1B

Fiscal Period: December	2020	2021	2022	2023	2024
Net Income	279M	966M	1.09B	1.36B	1.37B
Depreciation & Amortization - CF	134M	147M	160M	151M	149M
Amortization of Goodwill and Intangible Assets - (CF)	886M	906M	551M	499M	493M
Depreciation & Amortization, Total	1.02B	1.05B	711M	650M	642M
Amortization of Deferred Charges, Total - (CF)	285M	228M	434M	493M	493M
(Gain) Loss From Sale Of Asset	-	-	-10M	-	-
(Gain) Loss on Sale of Investments - (CF)	-25M	-16M	27M	-20M	-22M
Asset Writedown & Restructuring Costs	-	-	-	-	-
(Income) Loss On Equity Investments - (CF)	-7M	-6M	12M	-	-5M
Stock-Based Compensation (CF)	95M	170M	194M	217M	206M
Tax Benefit from Stock Options	-	-	-	-	-
Other Operating Activities, Total	-147M	-133M	-115M	-269M	-129M
Change In Accounts Receivable	255M	-138M	-421M	-388M	182M
Change In Accounts Payable	253M	244M	427M	267M	115M
Change in Unearned Revenues	180M	591M	31M	-29M	9M
Change In Income Taxes	-83M	-2M	-128M	-164M	-155M
Change in Other Net Operating Assets	-146M	-15M	7M	34M	7M
Cash from Operations	1.96B	2.94B	2.26B	2.15B	2.72B
Capital Expenditure	-616M	-640M	-674M	-649M	-602M
Sale of Property, Plant, and Equipment	-	-	-	-	25M
Cash Acquisitions	-177M	-1.46B	-1.32B	-876M	-735M
Divestitures	-	-	-	-	-
Investment in Marketable and Equity Securities, Total	-1M	-10M	-25M	-83M	-134M
Other Investing Activities, Total	-2M	5M	8M	5M	2M
Cash from Investing	-796M	-2.1B	-2.01B	-1.6B	-1.44B
Long-Term Debt Issued, Total	2.84B	2.76B	3.6B	6.38B	1.68B
Total Debt Issued	2.84B	2.76B	3.6B	6.38B	1.68B
Long-Term Debt Repaid, Total	-2.5B	-2.69B	-2.66B	-5.58B	-1.13B
Total Debt Repaid	-2.5B	-2.69B	-2.66B	-5.58B	-1.13B
Issuance of Common Stock	-	-	-	-	-
Repurchase of Common Stock	-447M	-406M	-1.17B	-992M	-1.35B
Other Financing Activities, Total	-112M	-899M	-102M	-192M	-81M
Cash from Financing	-217M	-1.24B	-329M	-382M	-878M
Foreign Exchange Rate Adjustments	31M	-52M	-75M	-4M	-68M
Net Change in Cash	977M	-448M	-150M	160M	326M
Supplemental Items
Cash Interest Paid	399M	343M	379M	-	-
Cash Income Tax Paid (Refund)	209M	222M	255M	340M	295M
Levered Free Cash Flow	1.48B	1.97B	1.37B	1.35B	1.84B
Unlevered Free Cash Flow	1.72B	2.19B	1.61B	1.75B	2.24B
Change In Net Working Capital	-447M	-494M	202M	239M	-94M
Net Debt Issued / Repaid	342M	70M	941M	802M	553M

Fiscal Period: December	2020	2021	2022	2023	2024
Profitability
Return on Assets	2.12	3.67	4.65	4.98	5.32
Return on Total Capital	2.67	4.75	6.18	6.61	7.01
Return On Equity %	4.91	15.76	18.48	22.87	22.55
Return on Common Equity	4.65	16.04	18.48	22.87	22.55
Margin Analysis
Gross Profit Margin %	33.97	33.45	34.89	34.96	34.89
SG&A Margin	15.51	13.92	14.14	13.63	12.87
EBITDA Margin %	16.11	18.01	17.84	18.16	18.96
EBITA Margin %	14.93	16.95	16.73	17.15	17.99
EBIT Margin %	7.13	10.42	12.91	13.82	14.79
Income From Continuing Operations Margin %	2.71	7	7.57	9.06	8.91
Net Income Margin %	2.46	6.96	7.57	9.06	8.91
Net Avail. For Common Margin %	2.46	6.96	7.57	9.06	8.91
Normalized Net Income Margin	1.95	5.01	6.03	6.14	6.69
Levered Free Cash Flow Margin	13.01	14.23	9.48	8.99	11.94
Unlevered Free Cash Flow Margin	15.14	15.8	11.18	11.67	14.52
Asset Turnover
Asset Turnover	0.48	0.56	0.58	0.58	0.58
Fixed Assets Turnover	11.91	14.95	16.32	17.82	19.35
Receivables Turnover (Average Receivables)	4.55	5.59	5.27	4.76	4.68
Short Term Liquidity
Current Ratio	1.12	0.91	0.89	0.86	0.84
Quick Ratio	0.96	0.78	0.77	0.76	0.73
Operating Cash Flow to Current Liabilities	0.43	0.56	0.41	0.33	0.39
Days Sales Outstanding (Average Receivables)	80.42	65.26	69.25	76.71	78.22
Average Days Payable Outstanding	28.21	23.76	24.63	25.36	26.36
Long Term Solvency
Total Debt/Equity	210.8	211.65	231.59	233.67	238.73
Total Debt / Total Capital	67.82	67.91	69.84	70.03	70.48
LT Debt/Equity	205.94	207.68	226.94	219.34	218.05
Long-Term Debt / Total Capital	66.26	66.64	68.44	65.74	64.37
Total Liabilities / Total Assets	74.43	75.53	77.25	77.09	77.45
EBIT / Interest Expense	1.95	3.86	4.47	3.08	3.4
EBITDA / Interest Expense	4.9	7.15	6.59	4.29	4.6
(EBITDA - Capex) / Interest Expense	3.42	5.45	4.97	3.32	3.7
Total Debt / EBITDA	6.49	4.77	4.87	4.96	4.7
Net Debt / EBITDA	5.56	4.22	4.39	4.44	4.11
Total Debt / (EBITDA - Capex)	9.3	6.26	6.46	6.4	5.85
Net Debt / (EBITDA - Capex)	7.97	5.54	5.82	5.73	5.1
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	2.44	22.14	3.86	3.98	2.81
Gross Profit, 1 Yr. Growth %	1.87	20.26	8.34	4.2	2.6
EBITDA, 1 Yr. Growth %	-2.71	36.56	2.88	5.83	7.35
EBITA, 1 Yr. Growth %	-3.25	38.68	2.51	6.59	7.86
EBIT, 1 Yr. Growth %	-7.43	78.52	28.63	11.34	10.04
Earnings From Cont. Operations, 1 Yr. Growth %	35.68	215.26	12.36	24.47	1.1
Net Income, 1 Yr. Growth %	46.07	246.24	12.94	24.47	1.1
Normalized Net Income, 1 Yr. Growth %	5.1	213.87	24.98	5.75	12.03
Diluted EPS Before Extra, 1 Yr. Growth %	48.96	246.15	15.56	27.45	2.74
Accounts Receivable, 1 Yr. Growth %	-6.66	5.85	14.35	15.91	-5.24
Net Property, Plant and Equip., 1 Yr. Growth %	-0.1	-5.25	-4.43	-5.1	-5.62
Total Assets, 1 Yr. Growth %	5.65	0.51	2.62	5.3	0.82
Tangible Book Value, 1 Yr. Growth %	1.61	2.9	6.34	2.45	-1.14
Common Equity, 1 Yr. Growth %	-0.03	0.68	-4.58	6.02	-0.74
Cash From Operations, 1 Yr. Growth %	38.25	50.18	-23.18	-4.91	26.38
Capital Expenditures, 1 Yr. Growth %	5.84	3.9	5.31	-3.71	-7.24
Levered Free Cash Flow, 1 Yr. Growth %	26.64	20.89	-34.96	-9.12	26.51
Unlevered Free Cash Flow, 1 Yr. Growth %	19.99	16.88	-30.48	1.27	20.53
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	4.45	11.86	12.63	3.92	3.39
Gross Profit, 2 Yr. CAGR %	2.6	10.69	14.15	6.25	3.39
EBITDA, 2 Yr. CAGR %	0.97	15.26	18.53	4.35	6.59
EBITA, 2 Yr. CAGR %	0.78	15.83	19.23	4.53	7.23
EBIT, 2 Yr. CAGR %	-1.39	28.55	51.54	19.68	10.69
Earnings From Cont. Operations, 2 Yr. CAGR %	4.14	106.82	88.21	18.26	12.18
Net Income, 2 Yr. CAGR %	3.79	124.89	97.75	18.57	12.18
Normalized Net Income, 2 Yr. CAGR %	-5.96	81.62	98.06	14.96	8.85
Diluted EPS Before Extra, 2 Yr. CAGR %	7.39	127.07	100	21.36	14.43
Accounts Receivable, 2 Yr. CAGR %	0.33	-0.6	10.02	15.12	4.8
Net Property, Plant and Equip., 2 Yr. CAGR %	48.18	-2.71	-4.84	-4.76	-5.36
Total Assets, 2 Yr. CAGR %	4.37	3.05	1.56	3.96	3.04
Tangible Book Value, 2 Yr. CAGR %	3.65	2.25	4.61	4.38	0.64
Common Equity, 2 Yr. CAGR %	-5.46	0.32	-1.99	0.58	2.59
Cash From Operations, 2 Yr. CAGR %	24.99	44.09	7.41	-14.53	9.63
Capital Expenditures, 2 Yr. CAGR %	15.85	4.86	4.6	0.7	-5.49
Levered Free Cash Flow, 2 Yr. CAGR %	17.95	30.1	-8.56	-19.92	11.4
Unlevered Free Cash Flow, 2 Yr. CAGR %	14.58	23.68	-7.33	-13.13	13.81
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	5.4	10.04	9.13	9.67	3.55
Gross Profit, 3 Yr. CAGR %	4.3	8.18	9.9	10.73	5.02
EBITDA, 3 Yr. CAGR %	3.26	11.66	10.98	14.14	5.34
EBITA, 3 Yr. CAGR %	3.34	12.09	11.21	14.86	5.63
EBIT, 3 Yr. CAGR %	1.05	20.18	28.58	36.74	16.37
Earnings From Cont. Operations, 3 Yr. CAGR %	-38.06	50.65	68.76	63.98	12.24
Net Income, 3 Yr. CAGR %	-39.77	55.08	78.76	69.47	12.43
Normalized Net Income, 3 Yr. CAGR %	-2.76	40.53	60.35	60.68	13.98
Diluted EPS Before Extra, 3 Yr. CAGR %	-37.08	58.63	81.29	72.11	14.8
Accounts Receivable, 3 Yr. CAGR %	4.75	2.14	4.15	11.95	7.89
Net Property, Plant and Equip., 3 Yr. CAGR %	29.38	27.66	-3.29	-4.93	-5.05
Total Assets, 3 Yr. CAGR %	2.43	3.07	2.91	2.79	2.9
Tangible Book Value, 3 Yr. CAGR %	4.32	3.4	3.6	3.88	2.5
Common Equity, 3 Yr. CAGR %	-9.12	-3.45	-1.34	0.61	0.14
Cash From Operations, 3 Yr. CAGR %	26.4	32.88	16.84	3.13	-2.63
Capital Expenditures, 3 Yr. CAGR %	18.63	11.72	5.01	1.75	-2.02
Levered Free Cash Flow, 3 Yr. CAGR %	13.09	22.97	5.39	-6.24	-4.32
Unlevered Free Cash Flow, 3 Yr. CAGR %	11.85	18.73	3.97	-2.31	-1.17
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	21.3	15.28	8.23	7.55	6.8
Gross Profit, 5 Yr. CAGR %	18.94	17.56	8.13	7.4	7.25
EBITDA, 5 Yr. CAGR %	18.96	19.86	9.12	8.68	9.2
EBITA, 5 Yr. CAGR %	19.12	20.36	9.42	9	9.6
EBIT, 5 Yr. CAGR %	3.62	13.58	18.83	19.98	21.1
Earnings From Cont. Operations, 5 Yr. CAGR %	-4.51	62.01	-3.39	36.75	43.33
Net Income, 5 Yr. CAGR %	-6.33	68.08	-3.1	39.29	48.36
Normalized Net Income, 5 Yr. CAGR %	-9.75	13.5	29.25	29.69	37.33
Diluted EPS Before Extra, 5 Yr. CAGR %	-14.23	60.14	-0.07	42.52	50.81
Accounts Receivable, 5 Yr. CAGR %	15.63	8.37	6.82	7.15	4.41
Net Property, Plant and Equip., 5 Yr. CAGR %	38.35	17.34	14.42	13.54	-4.12
Total Assets, 5 Yr. CAGR %	44.3	3.09	2.08	3.42	2.96
Tangible Book Value, 5 Yr. CAGR %	48.32	7.54	4.43	3.79	2.4
Common Equity, 5 Yr. CAGR %	60.47	-6.89	-6.33	-1.86	0.21
Cash From Operations, 5 Yr. CAGR %	32.7	27.89	18.43	11.38	13.9
Capital Expenditures, 5 Yr. CAGR %	51.18	31.3	12.8	7.17	0.68
Levered Free Cash Flow, 5 Yr. CAGR %	30.95	13.83	5.98	4.86	9.53
Unlevered Free Cash Flow, 5 Yr. CAGR %	31.46	14.93	5.56	5.95	9.31